세계의 신경퇴행성 질환 시장 : 적응증별, 약제 클래스별, 유통 채널별, 지역별 - 기회 및 예측(2018-2032년)

Global neurodegenerative disease market is projected to witness a CAGR of 7.51% during the forecast period 2025-2032, growing from USD 55.21 billion in 2024 to USD 98.54 billion in 2032. The global neurodegenerative disease is experiencing rapid growth due to a growing population, investment in research and development, and innovation in therapeutic drugs.

The neurodegenerative disease market is undergoing significant growth, due to the increasing aging global population, leading to many instances of Alzheimer's and Parkinson's disease. The growth is also due to the increasing investment in developing new biomarkers or diagnostics to not only manage the symptoms of the disease but also to intervene on the disease itself. Additional strong trends in space are the move towards precision medicine with new genetic technologies or biomarkers, and the change from symptomatic therapies to disease-modifying therapies and targeting earlier stages of neurodegenerative disease. Despite the challenges of complexity (and drug development costs) in discovery and clinical development of these diseases, there are significant opportunities in technology and innovation, continuing government and private investments in medical research, and identifying new markets that have significant unmet medical needs.

Additionally, to support the neurodegenerative disease market in May 2025, Sanofi S.A. announced that enter into a transaction for Vigil Neuroscience, Inc., a clinical-stage biotechnology company that is publicly traded and develops novel therapies for people with neurodegenerative diseases. It also strengthens Sanofi's early-stage pipeline and provides entry into a phase 2 clinical study of VG-3927, an oral small-molecule TREM2 agonist, in Alzheimer's disease.

Increase in Population and Growing Awareness Support Market Expansion

The growing aging population and rising awareness concerning diseases are major drivers of the global market. As life expectancy increases, the risk of age-related diseases such as Alzheimer's and Parkinson's will ramp up demand for standard of care diagnostic tools, treatments, and long-term care post-diagnosis for an exponentially larger pool of patients. Significant research and development investments will emerge due to the combined effects of rising healthcare demand and the system's current overcapacity. The medical research funding will prioritize innovative disease-modifying treatments alongside advanced AI and digital health technologies. The increased public knowledge and efforts to detect neurodegenerative disorders sooner will generate greater market interest. A new generation of treatment models will develop which will deliver a better quality of life to vast populations dealing with these disorders. The new advancements will work toward creating medical solutions that can either reduce the rate of disease progression or completely stop its progression.

Additionally, to support aging populations who are affected by neurodegenerative disease, in March 2023, the Government of Canada announced it to invest USD 38.3 million in a research study to address the challenges of aging and brain health issues, including dementia, and provide quality of life for the aging population of Canada.

Rise in Investment in R&D Activities Boosts Market Demand

The market witnesses a rise in consumer demand as companies invest in research and development for the creation of new products. Organizations use research and development to detect unaddressed customer requirements and sometimes foresee upcoming market needs. Proper foresight plays an essential role because successful R&D work generates innovative solutions that customers enthusiastically adopt. Several types of innovation, including feature additions, performance enhancements, efficiency improvements, and brand-new functions, drive global market growth. The development of new product features enables companies to compete for customer choice. Companies conduct research and development work to enhance production processes, which helps them minimize manufacturing expenses. The cost savings resulting from better production processes permit companies to decrease their pricing to reach new customer groups. In addition, federations globally are announcing funds to address the rising demand and advancement in drug development.

For instance, in September 2023, the FDA announced that it has awarded over USD 16.9 million in funding over a next four-year period for important research through its Rare Neurodegenerative Disease Grant Program, including studies for amyotrophic lateral disease (ALS), and other rare neurodegenerative diseases, such as Niemann-Pick type C and myotonic dystrophy type 1.

Alzheimer's Diseases Holds Largest Global Neurodegenerative Disease Market Share

Alzheimer's Disease (AD) has the largest market share in neurodegenerative diseases, based primarily on the extent of its burden, with dementia being the most prevalent and common form, and the rapid growth of the aged population across the world. New disease-modifying therapies have brought about revolutionary market expansion through their ability to attack the root causes of diseases instead of basic symptoms. The growing burden of disease receives continuous research and development support, which drives advancements in drug development and diagnostic technology. The persistent dedication to research and development efforts keeps Alzheimer's disease at the forefront of medical institutions' focus for therapeutic and diagnostic solutions.

For instance, in December 2023, according to the Alzheimer's Association's report, about 6.7 million individuals aged 65 and older in the U.S. have Alzheimer's disease and estimates project to rise to 13.8 million by 2060.

North America Dominates Neurodegenerative Disease Market

North America has the dominant share of the neurodegenerative disease market due to its high prevalence, a well-established health care system, and an R&D commitment. Drug development leaders are in the United States, with Biogen (Alzheimer's), AbbVie (Parkinson's), and Ionis Pharmaceuticals (ALS) leading the innovation front. Other aspects of the region that promote growth are the upside in easy-to-access reimbursement from publicly funded insurance (Medicare) and private insurers, and an increasing aging population. North America also conducts significantly more clinical trials for screening and drugs for neurodegenerative disease therapies than other regions, which reduces the time to approval.

Additionally, to support health care infrastructure and clinical trial in March 2024

United State Congress approved a USD 100 million funding for National Institute of Health (NIH) to support Alzheimer's and dementia research for fiscal year 2024, and USD 34 million to support the BOLD Infrastructure Act an aspirational, bipartisan priority championed by the Alzheimer's Association and Alzheimer's Impact Movement (AIM). To receive such investment, scientists need to drive innovation and quality of treatment to prevent Alzheimer's.

Impact of U.S. Tariffs on the Global Neurodegenerative Disease Market

The U.S. tariffs will create substantial effects on the market for neurodegenerative diseases because they will boost expenses and disrupt pharmaceutical and medical equipment distribution networks. Cough suppressants and Alzheimer's and Parkinson's, and ALS medications depend on active pharmaceutical ingredients that enter the country through imports. Tariffs imposed on these items would result in higher production expenses, which would indirectly cause patients to pay increased costs for their treatments. Patients could experience treatment delays because of supply chain problems. The imposition of potential retaliatory tariffs would result in decreased exports of U.S.-made drugs to foreign markets, which would further burden the sector. The implementation of tariffs would place financial pressure on smaller biotech firms, which currently serve as the main drivers of innovation within the industry. The financial constraints would lead to decreased research in new drugs and result in delayed development of economically feasible treatment methods.

Key Players Landscape and Outlook

Continuous innovation characterizes the landscape of neurodegenerative disease globally, as companies are making substantial investments in research, pursuing strategic partnerships, and accelerating the launch of new products. Gene therapies and RNA-targeting drugs are a primary focus and will be major drivers of growth. The future looks bright, fueled by an aging global population and recent breakthroughs in neuroscience, along with increased investments in precision medicine, AI-assisted drug discovery, and diagnostics.

In January 2025, Eisai Co., Ltd. and Biogen, Inc. jointly announced that they received a grant from the U.S. Food and Drug Administration (FDA) approval for a supplemental Biologics License Application for lecanemab-irmb to maintain the dosing regimen of once every four weeks and offers a potentially more convenient treatment option for eligible patients.

In January 2024, AbbVie Inc. launched PRODUODOPA treatment for advanced Parkinson's, a disease with severe motor-like fluctuations and involuntary movement. It helps patients by extending the period when symptoms are well-controlled by other therapies.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Neurodegenerative Diseases Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Indication
    • 5.2.1.1. Alzheimer's Disease
    • 5.2.1.2. Parkinson's Disease
    • 5.2.1.3. Amyotrophic Lateral Sclerosis
    • 5.2.1.4. Huntington's Disease
    • 5.2.1.5. Other Indications
  • 5.2.2. By Drug Class
    • 5.2.2.1. N-methyl-D-aspartate (NMDA) Receptor Antagonists
    • 5.2.2.2. Cholinesterase Inhibitors
    • 5.2.2.3. Dopamine Agonists
    • 5.2.2.4. Immunomodulatory Drugs
    • 5.2.2.5. Other Drug Classes
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
    • 5.2.3.4. Others
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Indication
  • 5.3.2. By Drug Class
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Neurodegenerative Diseases Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Indication
    • 6.2.1.1. Alzheimer's Disease
    • 6.2.1.2. Parkinson's Disease
    • 6.2.1.3. Amyotrophic Lateral Sclerosis
    • 6.2.1.4. Huntington's Disease
    • 6.2.1.5. Other Indications
  • 6.2.2. By Drug Class
    • 6.2.2.1. N-methyl-D-aspartate (NMDA) Receptor Antagonists
    • 6.2.2.2. Cholinesterase Inhibitors
    • 6.2.2.3. Dopamine Agonists
    • 6.2.2.4. Immunomodulatory Drugs
    • 6.2.2.5. Other Drug Classes
  • 6.2.3. By Distribution Channel
    • 6.2.3.1. Hospital Pharmacies
    • 6.2.3.2. Retail Pharmacies
    • 6.2.3.3. Online Pharmacies
    • 6.2.3.4. Others
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Neurodegenerative Diseases Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Indication
        • 6.3.1.2.1.1. Alzheimer's Disease
        • 6.3.1.2.1.2. Parkinson's Disease
        • 6.3.1.2.1.3. Amyotrophic Lateral Sclerosis
        • 6.3.1.2.1.4. Huntington's Disease
        • 6.3.1.2.1.5. Other Indications
      • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.2.1. N-methyl-D-aspartate (NMDA) Receptor Antagonists
        • 6.3.1.2.2.2. Cholinesterase Inhibitors
        • 6.3.1.2.2.3. Dopamine Agonists
        • 6.3.1.2.2.4. Immunomodulatory Drugs
        • 6.3.1.2.2.5. Other Drug Classes
      • 6.3.1.2.3. By Distribution Channel
        • 6.3.1.2.3.1. Hospital Pharmacies
        • 6.3.1.2.3.2. Retail Pharmacies
        • 6.3.1.2.3.3. Online Pharmacies
        • 6.3.1.2.3.4. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Neurodegenerative Diseases Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Neurodegenerative Diseases Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Neurodegenerative Diseases Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Neurodegenerative Diseases Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Supply Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

• 17.1. Market Drivers
• 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework and Innovation

• 19.1. Clinical Trials
• 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

• 22.1. Competition Matrix of Top 5 Market Leaders
• 22.2. SWOT Analysis for Top 5 Players
• 22.3. Key Players Landscape for Top 10 Market Players
  • 22.3.1. AbbVie Inc.
    • 22.3.1.1. Company Details
    • 22.3.1.2. Key Management Personnel
    • 22.3.1.3. Products and Services
    • 22.3.1.4. Financials (As Reported)
    • 22.3.1.5. Key Market Focus and Geographical Presence
    • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 22.3.2. Novartis AG
  • 22.3.3. Merck & Co., Inc
  • 22.3.4. Biogen, Inc.
  • 22.3.5. Teva Pharmaceutical Industries Ltd.
  • 22.3.6. Pfizer Inc.
  • 22.3.7. Sanofi S.A
  • 22.3.8. GlaxoSmithKline PLC
  • 22.3.9. UCB S.A.
  • 22.3.10. H. Lundbeck A/S
  • 22.3.11. Boehringer Ingelheim International GmbH

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer